PLATFORM Study of Precision Medicine for Rare Tumors

Summary

A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.

Conditions

• Rare Tumor

Interventions

DRUG

Almonertinib 110 MG

Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.

DRUG

Dacomitinib 45 MG

Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.

DRUG

Alectinib 150 MG

Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.

DRUG

Crizotinib 250 MG

Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.

DRUG

Pyrotinib 160/80 MG

Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.

DRUG

Imatinib 400 MG

Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.

DRUG

Niraparib 200/300 MG

Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.

DRUG

Palbociclib 125mg

Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.

DRUG

Vemurafenib 240 MG

Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.

DRUG

Sintilimab 100MG

Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.

DRUG

Atezolizumab 1680 MG

Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.

Sponsors & Collaborators

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  lead OTHER

Principal Investigators

• Ning Li, Doctor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-08-15

Primary Completion

2026-07-01

Completion

2028-07-01

Countries

• China

Study Locations